Transglutaminase-isoenzyme specific glutamine donor substrates identified by Kiyotaka Hitomi et al. at Nagoya University, Japan.
Molecular Formula
C79H108N20O22S2
Molecular Weight
1753.95
Purity by HPLC
>95 % (214 nm)
Purity
>95 % (214 nm)
Appearance
white powder
Solubility
stock solution: 100 mM in DMSO cassay 500 μM
Application
Transglutaminase specific glutamine donor substrate
Storage
store at -20°C, desiccate
Reference(s)
Sugimura, Y. et al. J. Biol. Chem. 2006, 281, 17699. Sugimura, Y. et al. FEBS J. 2008, 275, 5667. Yamane, A. et al. FEBS J. 2010, 277, 3564. Schulze-Krebs, A. et al. Brain Res. 2016, 1631, 22. van der Wildt, B. et al. Nucl. Med. Biol. 2016, 43, 232. Itoh, M. et al. J. Histochem. Cytochem. 2013, 61, 793.
Note
INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.
LinkBesuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira
LinkDiscover Our New Catalogue Edition and Dive into the World of Transglutaminases!
Link Co-authored article: The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment
Link Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Link Kooperations- und Lizenzvereinbarung zwischen Takeda, Zedira und Dr. Falk Pharma zur Entwicklung einer First-in-Class-Therapie für die Zöliakie
Link Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
Link Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
Link Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
LinkDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
LinkDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
LinkReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Blog
LinkTransglutaminase antibodies and neurological manifestations of gluten sensitivity
Link DZG Aktuell: Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227
LinkDesign of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible?
LinkMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering